Seems like people are ignoring the previous advice from the company.
FebriDx was late to the table for the US flu season with the majority of supplies having been contracted in the September quarter so revenue from this product was always going to be on the low side initially with the expectation for this to build into the upcoming US flu season.
It seems to me that LDX was oversold on the quarterly result as they just don't understand the company, it would have been better if they could have aligned the quarterly release and the investor briefing for the same day.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-43
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 3.9¢ | $100.6K | 2.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 623990 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 298309 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| LDX (ASX) Chart |